id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2006-D-0032-0005,FDA,FDA-2006-D-0032,FDA,Notice,NAD-Notice of Availability of Data,2006-12-22T05:00:00Z,2006,12,2006-12-21T05:00:00Z,,2008-04-11T22:52:06Z,,0,0,09000064804420d6
FDA-2006-D-0032-0007,FDA,FDA-2006-D-0032,Guidance,Supporting & Related Material,GDL-Guidance,2006-12-22T05:00:00Z,2006,12,,,2008-04-11T22:52:06Z,,0,0,09000064804420d8
FDA-2006-D-0032-0006,FDA,FDA-2006-D-0032,"Guidance for Clinical Investigators, Institutional Review Boards and Sponsors; Process for Handling Referrals to FDA Under 21 CFR 50.54;  Additional Safeguards for Children in Clinical Investigations",Other,Guidance,2006-12-01T05:00:00Z,2006,12,2006-12-01T05:00:00Z,,2024-11-12T04:12:33Z,,1,0,09000064804420d7
FDA-2006-D-0032-0002,FDA,FDA-2006-D-0032,Draft Guidance,Supporting & Related Material,GDL-Guidance,2006-05-10T04:00:00Z,2006,5,,,2008-04-11T22:52:06Z,,0,0,09000064804420cd
FDA-2006-D-0032-0001,FDA,FDA-2006-D-0032,FDA,Notice,NAD-Notice of Availability of Data,2006-05-10T04:00:00Z,2006,5,2006-05-10T04:00:00Z,2006-07-11T03:59:59Z,2008-04-11T22:52:06Z,,0,0,09000064804420c8
FDA-2006-D-0032-0003,FDA,FDA-2006-D-0032,Draft Guidance,Supporting & Related Material,GDL-Guidance,2006-05-10T04:00:00Z,2006,5,,,2008-04-11T22:52:06Z,,0,0,09000064804420ce
FDA-2006-D-0032-0004,FDA,FDA-2006-D-0032,Draft Guidance,Supporting & Related Material,GDL-Guidance,2006-05-10T04:00:00Z,2006,5,,,2008-04-11T22:52:06Z,,0,0,09000064804420cf